Listening carefully to our physician partners, our engineers and scientists have applied their spirit of innovation to the complexities of endovascular repair. The result: a new system that offers clinicians greater control for durable outcomes.

Controlled.
Conformable.
Predictable.

We lead the way in TEVAR innovation.

- The first thoracic stent graft approved in Europe, U.S., and Japan*
- The first TEVAR device to reach 100,000 devices distributed
- The first device approved for endovascular treatment of aneurysms, transections, and Type B dissections
- The first to feature a new delivery system that offers controlled, staged deployment
- 20 years of TEVAR experience

* Conformable GORE® TAG® device

Learn more at goremedical.com/predictable

Introducing
the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
Even patients with complex anatomical challenges such as acute aortic angles can benefit from the GORE® ACTIVE CONTROL System.

Now, endovascular repair of aneurysms, transections, and Type B dissections can be carried out with greater precision than ever.

**Controlled.**

The GORE® ACTIVE CONTROL System is a purpose-built new delivery system that offers controlled, staged deployment.

**Conformable.**

Patients have individual anatomies with unique challenges. The GORE® ACTIVE CONTROL System harnesses the exceptional conformability of the stent graft, facilitating the optimized seal opposition that the Conformable GORE® TAG® Device is known for.

**Predictable.**

Built on the established success of the Conformable GORE® TAG® Device, which has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

* Consolidated outcomes following 5 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.

Controlled. Deployed with GORE® ACTIVE CONTROL System, the new delivery system is designed to optimize accuracy, angulation, and apposition.


Based on the established success of the Conformable GORE® TAG® Device that has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

Purpose-built to deliver new levels of control, with precise placement and trusted conformability.

---

**Proven results in complex procedures.**

The new system builds on the established success of the Conformable GORE® TAG® Device, which has demonstrated strong results in aneurysms, transections, and acute and chronic Type B dissections.*

* Consolidated outcomes following 6 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.

**Controlled.**

The GORE® ACTIVE CONTROL System is the first to feature a new delivery system that offers controlled, staged deployment.

**Conformable.**

Patients have individual anatomies with unique challenges. The GORE® ACTIVE CONTROL System harnesses the exceptional conformability of the stent graft, facilitating the optimized seal opposition that the Conformable GORE® TAG® Device is known for.

**Predictable.**

Built on the established success of the Conformable GORE® TAG® Device, which has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

* Consolidated outcomes following 5 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.

Controlled. Deployed with GORE® ACTIVE CONTROL System, the new delivery system is designed to optimize accuracy, angulation, and apposition.


Based on the established success of the Conformable GORE® TAG® Device that has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

Purpose-built to deliver new levels of control, with precise placement and trusted conformability.

---

**Proven results in complex procedures.**

The new system builds on the established success of the Conformable GORE® TAG® Device, which has demonstrated strong results in aneurysms, transections, and acute and chronic Type B dissections.*

* Consolidated outcomes following 6 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.

**Controlled.**

The GORE® ACTIVE CONTROL System is the first to feature a new delivery system that offers controlled, staged deployment.

**Conformable.**

Patients have individual anatomies with unique challenges. The GORE® ACTIVE CONTROL System harnesses the exceptional conformability of the stent graft, facilitating the optimized seal opposition that the Conformable GORE® TAG® Device is known for.

**Predictable.**

Built on the established success of the Conformable GORE® TAG® Device, which has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

* Consolidated outcomes following 5 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.

Controlled. Deployed with GORE® ACTIVE CONTROL System, the new delivery system is designed to optimize accuracy, angulation, and apposition.


Based on the established success of the Conformable GORE® TAG® Device that has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

Purpose-built to deliver new levels of control, with precise placement and trusted conformability.